Persistence Market Research Blog

Posts tagged ‘Next-Generation Antibody Therapeutics Industry’

Next-Generation Antibody Therapeutics Market: Global Industry Analysis and Forecast to 2020

Next-generation antibody based therapeutics refers to the use of new and improved therapeutic antibody to create innovative medicines for the treatment of various diseases. Next-generation antibody therapeutics is developed clinically by biotechnology and pharmaceutical companies for various diseases indication. These new therapeutic antibodies are developed with the special features such as increased selectivity and enhance efficacy. Technological advancement such as antibody drug conjugates (ADCs), success of monoclonal antibody (MAb) and antibody-derived therapeutics and increasing demand for biological drugs for the treatment for various chronic diseases are some of the main factors which helps to drive the market. On the basis of technology, next-generation antibody therapeutics market can be segmented into engineered antibodies, bispecific antibodies (bisAbs), antibody-drug conjugates (ADCs), antibody fragments and antibody-like proteins and biosimilar antibody products. ADCs are composed by linking of an antibody with cytotoxic drugs. On the basis of platform, next-generation antibody therapeutics market can be segmented into BioWa. Glycart and xencor. On the basis of therapeutic area, next-generation antibody therapeutics market can be segmented into oncology, autoimmune/inflammatory, haemostasis, ocular disorders, various infectious diseases and others.

Complete report available at Global Next-Generation Antibody Therapeutics Market

Advertisements

Tag Cloud